Lofexidine Gets US FDA Panel Nod For Mitigating Opioid Withdrawal Symptoms

But Psychopharmacologic Drugs Advisory Committee says US WorldMeds' second proposed indication for facilitating completion of opioid discontinuation treatment is not supported by data from two short-term studies in an 'idealized' population.

FDA Advisory Committee Feature image

A US FDA advisory committee on March 27 recommended approval of US WorldMeds LLC's opioid withdrawal drug Lucemyra (lofexidine) but for a narrower indication than requested and for the lower of two doses studied in the Phase III trials.

If FDA follows the recommendations of the majority of its external advisors, lofexidine would be labeled for the mitigation of...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from US FDA Performance Tracker

More from Regulatory Trackers